Impaired glucose metabolism among those with and without diagnosed diabetes and mortality: A cohort study using Health Survey for England data

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Gordon Dseagu, Vanessa L Z ^a   Mindell, Jennifer S ^a   Steptoe, Andrew ^a   Moody, Alison ^a   Wardle, Jane ^a   Demakakos, Panayotes ^a   Shelton, Nicola J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HEALTH CARE POLICY; HEALTH SURVEY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; SEX DIFFERENCE; SOCIAL ASPECT; UNITED KINGDOM; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; EPIDEMIOLOGY; INCIDENCE; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASMS; PREDIABETIC STATE; RISK FACTOR; SOCIAL CLASS; SURVIVAL ANALYSIS;

ADULT; AGED; BIOMARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HEALTH SURVEYS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PREDIABETIC STATE; RISK FACTORS; SEX FACTORS; SOCIAL CLASS; SURVIVAL ANALYSIS; UNITED KINGDOM;

EID: 84925729329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119882     Document Type: Article

References (42)

1. World Health Organization. Diabetes Factsheet No.312. 2011; Available: http://www.who.int/mediacentre/factsheets/fs312/en/
2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011; 94: 311-321. doi: 10.1016/j.diabres.2011.10.029 PMID: 22079683
3. Holman N, Forouhi NG, Goyder E, Wild SH. The Association of Public Health Observatories (APHO) Diabetes Prevalence Model: estimates of total diabetes prevalence for England, 2010-2030. Diabet Med J Br Diabet Assoc. 2011; 28: 575-582. doi: 10.1111/j.1464-5491.2010.03216.x PMID: 21480968
4. The International Expert Committee. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care. 2009; 32: 1327-1334. doi: 10.2337/dc09-9033 PMID: 19502545
5. Eskesen K, Jensen MT, Galatius S, Vestergaard H, Hildebrandt P, Marott JL, et al. Glycated haemoglobin and the risk of cardiovascular disease, diabetes and all-cause mortality in the Copenhagen City Heart Study. J Intern Med. 2013; 273: 94-101. doi: 10.1111/j.1365-2796.2012.02594.x PMID: 23009556
6. Xu L, Chan WM, Hui YF, Lam TH. Association between HbA1c and cardiovascular disease mortality in older Hong Kong Chinese with diabetes. Diabet Med J Br Diabet Assoc. 2012; 29: 393-398. doi: 10.1111/j.1464-5491.2011.03456.x PMID: 21916977
7. Andersson C, van Gaal L, Caterson ID, Weeke P, James WPT, Coutinho W, et al. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia. 2012; 55: 2348-2355. doi: 10.1007/s00125-012-2584-3 PMID: 22638548
8. Skriver MV, Støvring H, Kristensen JK, Charles M, Sandbæk A. Short-term impact of HbA1c on morbidity and all-cause mortality in people with type 2 diabetes: a Danish population-based observational study. Diabetologia. 2012; 55: 2361-2370. doi: 10.1007/s00125-012-2614-1 PMID: 22736395
9. Monami M, Vitale V, Lamanna C, Bartoli N, Martelli D, Zannoni S, et al. HbA1c levels and all-cause mortality in type 2 diabetic patients: epidemiological evidence of the need for personalised therapeutic targets. Nutr Metab Cardiovasc Dis NMCD. 2013; 23: 300-306. doi: 10.1016/j.numecd.2012.01.003 PMID: 22633797
10. Elley CR, Kenealy T, Robinson E, Drury PL. Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabet Med J Br Diabet Assoc. 2008; 25: 1295-1301. doi: 10.1111/j.1464-5491.2008.02581.x PMID: 19046219
11. Sakurai M, Saitoh S, Miura K, Nakagawa H, Ohnishi H, Akasaka H, et al. HbA1c and the risks for all-cause and cardiovascular mortality in the general Japanese population: NIPPON DATA90. Diabetes Care. 2013; 36: 3759-3765. doi: 10.2337/dc12-2412 PMID: 23877989
12. Khaw K-T, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004; 141: 413-420. PMID: 15381514
13. D browski M. Glycated hemoglobin, diabetes treatment and cancer risk in type 2 diabetes. A case-control study. Ann Agric Environ Med AAEM. 2013; 20: 116-121.
14. Joshu CE, Prizment AE, Dluzniewski PJ, Menke A, Folsom AR, Coresh J, et al. Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990-2006. Int J Cancer J Int Cancer. 2012; 131: 1667-1677. doi: 10.1002/ijc.27394 PMID: 22161730
15. Sluik D, Boeing H, Montonen J, Kaaks R, Lukanova A, Sandbaek A, et al. HbA1c measured in stored erythrocytes is positively linearly associated with mortality in individuals with diabetes mellitus. PloS One. 2012; 7: e38877. doi: 10.1371/journal.pone.0038877 PMID: 22719972
16. Miao Jonasson J, Cederholm J, Eliasson B, Zethelius B, Eeg-Olofsson K, Gudbjörnsdottir S. HbA1C and Cancer Risk in Patients with Type 2 Diabetes - A Nationwide Population-Based Prospective Cohort Study in Sweden. Barengo NC, editor. PLoS ONE. 2012; 7: e38784. doi: 10.1371/journal.pone.0038784 PMID: 22719946
17. Joshu CE, Prizment AE, Dluzniewski PJ, Menke A, Folsom AR, Coresh J, et al. Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990-2006. Int J Cancer J Int Cancer. 2012; 131: 1667-1677. doi: 10.1002/ijc.27394 PMID: 22161730
18. Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med. 2009; 6: e1000201. doi: 10.1371/journal.pmed.1000201 PMID: 20027213
19. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA J Am Med Assoc. 2005; 293: 194-202.
20. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal Glucose Tolerance and the Risk of Cancer Death in the United States. Am J Epidemiol. 2003; 157: 1092-1100. PMID: 12796045
21. De Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? Br J Cancer. 2014;
22. Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364: 829-841. doi: 10.1056/NEJMoa1008862 PMID: 21366474
23. Saydah S, Lochner K. Socioeconomic status and risk of diabetes-related mortality in the U.S. Public Health Rep Wash DC 1974. 2010; 125: 377-388.
24. Mindell J, Biddulph JP, Hirani V, Stamatakis E, Craig R, Nunn S, et al. Cohort Profile: The Health Survey for England. Int J Epidemiol. 2012;
25. Gray L, Batty GD, Craig P, Stewart C, Whyte B, Finlayson A, et al. Cohort profile: the Scottish health surveys cohort: linkage of study participants to routinely collected records for mortality, hospital discharge, cancer and offspring birth characteristics in three nationwide studies. Int J Epidemiol. 2010; 39: 345-350. doi: 10.1093/ije/dyp155 PMID: 19349480
26. Craig R, Mindell J, Hirani V. Health Survey for England 2008: Volume 2: Methods and documentation. London: The Health and Social Care Information Centre; 2009.
27. Craig R, Mindell J, Hirani V. Health Survey for England 2008: Volume 1: Physical activity and fitness. London: The Health and Social Care Information Centre; 2009.
28. Farmer A. Use of HbA1c in the diagnosis of diabetes. BMJ. 2012; 345: e7293-e7293. doi: 10.1136/bmj.e7293 PMID: 23118305
29. Huang Y, Cai X, Chen P, Mai W, Tang H, Huang Y, et al. Associations of prediabetes with all-cause and cardiovascular mortality: A meta-analysis. Ann Med. 2014; 1-9. doi: 10.3109/07853890.2014.969766 PMID: 25356772
30. Roche MM, Wang PP. Sex Differences in All-Cause and Cardiovascular Mortality, Hospitalization for Individuals With and Without Diabetes, and Patients With Diabetes Diagnosed Early and Late. Diabetes Care. 2013; 36: 2582-2590. doi: 10.2337/dc12-1272 PMID: 23564923
31. Joshu CE, Prizment AE, Dluzniewski PJ, Menke A, Folsom AR, Coresh J, et al. Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990-2006. Int J Cancer. 2012; 131: 1667-1677. doi: 10.1002/ijc.27394 PMID: 22161730
32. Gapstur SM, Gann PH, Colangelo LA, Barron-Simpson R, Kopp P, Dyer A, et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control CCC. 2001; 12: 763-772. PMID: 11562117
33. Selvin E, Coresh J, Golden SH, Boland LL, Brancati FL, Steffes MW, et al. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study. Diabetes Care. 2005; 28: 1965-1973. PMID: 16043740
34. Bao C, Yang X, Xu W, Luo H, Xu Z, Su C, et al. Diabetes mellitus and incidence and mortality of kidney cancer: A meta-analysis. J Diabetes Complications. 2013; 27: 357-364. doi: 10.1016/j.jdiacomp.2013.01.004 PMID: 23433629
35. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst. 1999; 91: 151-156. PMID: 9923856
36. Gallagher EJ, LeRoith D. Minireview: IGF, Insulin, and Cancer. Endocrinology. 2011; 152: 2546-2551. doi: 10.1210/en.2011-0231 PMID: 21540285
37. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp. 2004; 262: 247-260; discussion 260-268. PMID: 15562834
38. Östgren CJ, Sundström J, Svennblad B, Lohm L, Nilsson PM, Johansson G. Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care. Diabet Med J Br Diabet Assoc. 2013; 30: e170-177. doi: 10.1111/dme.12145 PMID: 23350893
39. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837-853. PMID: 9742976
40. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559. doi: 10.1056/NEJMoa0802743 PMID: 18539917
41. Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014; 2: CD009122. doi: 10.1002/14651858.CD009122.pub2 PMID: 24526393
42. ONS. Population Estimates by Ethnic Group 2002-2009. ONS; 2011 May.